Beta-blockers will continue to fall out of favor for hypertension

January 2013

Beta-blockers will continue to fall out of favor for hypertension...especially atenolol.

Beta-blockers seem to prevent fewer CV events in patients with hypertension than other BP meds...despite similar BP lowering.

Atenolol has a particularly bad reputation...because most hypertension trials evaluating cardiovascular risk used atenolol.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote